(Q36755228)

16 August 2017

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma (English)

1 reference

16 August 2017

1 reference

1 reference

J B Sørensen

1

1 reference

16 August 2017

H Frank

series ordinal

2

1 reference

16 August 2017

T Palshof

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

10 June 2008

1 reference

British Journal of Cancer

16 August 2017

1 reference

16 August 2017

99

1 reference

16 August 2017

1

1 reference

16 August 2017

44-50

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604421

16 August 2017

0 references

cites work

Assessment of tumor response in malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Pleural mesothelioma: little evidence, still time to do trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Emerging insights into the biology and therapy of malignant mesothelioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Can

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2453034

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

5 September 2018

1 reference

12 December 2020

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

12 December 2020

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

12 December 2020

Chemotherapy for malignant pleural mesothelioma: past results and recent developments

1 reference

12 December 2020

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma

1 reference

12 December 2020

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

12 December 2020

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma

1 reference

12 December 2020

Malignant pleural mesothelioma

1 reference

12 December 2020

Current concepts in chemotherapy for malignant pleural mesothelioma

1 reference

12 December 2020

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access program

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6604421

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

18542078

1 reference